Eye Infection Treatment Market is expected to be valued USD 9.9 Billion, at a CAGR of 3.8% from 2022 to 2030

Eye Infection Treatment Market
Eye Infection Treatment Market

Maintaining healthy vision is paramount, and the global Eye Infection Treatment Market reflects this growing focus. The market is estimated to have reached a value of USD 7.3 Billion in 2022 and is projected to experience steady growth at a Compound Annual Growth Rate (CAGR) of 3.8% through 2030. This translates to a projected market value of a staggering USD 9.9 Billion by 2030.

Rising Caseloads

Caseloads of ocular surgical conditions such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are growing due to sedentary lifestyle habits, and expanding geriatric cohort. According to the US statistics 2021, cataracts affect over 24 million Americans aging at least 40 years.

By age 75, about half of the Americans suffer from cataract. Further, diabetic retinopathy affects nearly 7.7 million Americans aging at least 40 years. Similarly, there were 48,229 corneal transplants performed in the US in 2015.

Demand for eye infection treatment will continue to receive a strong impetus from increasing awareness about different eye infection types and availability of treatment, further complemented by technological advancements on ophthalmology.

Request Sample PDF of this Report:

Key Takeaways of Eye Infection Treatment Market Study

  • Antibiotics would contribute over 55% revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
  • Eye drop sales capture over 60% market share in the eye infection treatment market.
  • Conjunctivitis would account for a third of eye infection treatment demand through 2030.
  • Bacterial infections continue to account for over 3/5th market share.
  • Hospitals and retail pharmacies collectively generate over 70% total returns to shareholders.
  • Increasing rate of eye surgeries and rising usage of contact lenses continue to push North American market. European market would be upheld by the expanding geriatric pool.

Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic

The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections.

According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.

Development and Licensing Deals with Multiple Commercialization Partners

Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies.

For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in Chinese market for ZERVIATE.

Ask for Customization:

Key Segments:

By Drug Class :

  • Antibiotics
    • Sulfonamides
    • Macrolides
    • Erythromycin
    • Chloramphenicol
    • Aminoglycosides
    • Fluoroquinolones
    • Vancomycin
    • Tetracyclines
  • Antivirals
    • Thymidine-Based Nucleoside Analogues (Trifluridine)
    • Thymidine Phosphorylase Inhibitors (Trifluridine)
    • Acyclic Nucleoside Analogue of 2’Deoxyguanasine (Ganciclovir)
    • Acyclic Guanine Nucleoside Analog (Acyclovir)
    • Others
  • Antifungals
    • Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
    • Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
    • Pyrimidines
    • Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
    • Others
  • Antihistamines
  • Corticosteroids
  • Glucocorticoids

By Dosage Form :

  • Eye Infections Treatment Tablets
  • Eye Infections Treatment Capsules
  • Eye Infections Treatment Ophthalmic Ointments
  • Eye Infections Treatment Eye Drops
  • Others

By Indication :

  • Eye Infections Treatment for Conjunctivitis
  • Eye Infections Treatment for Keratitis
  • Eye Infections Treatment for Endophthalmitis
  • Eye Infections Treatment for Blepharitis
  • Eye Infections Treatment for Stye or Sty (Hordeolum)
  • Eye Infections Treatment for Uveitis
  • Eye Infections Treatment for Cellulitis
  • Eye Infections Treatment for Ocular Herpes

By Causative Agent :

  • Virus
  • Bacteria
  • Fungus
  • Allergens

By Distribution Channels :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Region :

  • North America Eye Infections Treatment Market
  • Latin America Eye Infections Treatment Market
  • Europe Eye Infections Treatment Market
  • East Asia Eye Infections Treatment Market
  • South Asia & Pacific Eye Infections Treatment Market
  • Middle East & Africa (MEA) Eye Infections Treatment Market


Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these